Agios Pharmaceuticals, Inc. — 2016 Form 10-K
Reporting period: Fiscal year ended December 31, 2016. The filing also reports fourth-quarter results. Agios is a clinical-stage biopharmaceutical company focused on cellular metabolism in cancer and rare genetic metabolic disorders. It had no product-sales revenue; substantially all revenue was collaboration-related.
Financial performance and liquidity
| Metric | 2016 | 2015 |
|---|---|---|
| Collaboration revenue | $69.9 million | $59.1 million |
| Research and development expense, net | $220.2 million | $141.8 million |
| General and administrative expense | $50.7 million | $36.0 million |
| Operating loss | $201.0 million | $118.7 million |
| Net loss | $198.5 million | $117.7 million |
| Basic and diluted loss per share | $5.07 | $3.15 |
| Cash, cash equivalents and marketable securities at year-end | $573.6 million | $375.9 million |
| Operating cash flow | $38.6 million | $(76.9) million |
| Total assets / total liabilities | $619.1 million / $260.5 million | $420.1 million / $74.9 million |
Revenue increased 18.2%, while R&D expense rose 55.2% and net loss widened 68.6%. The increase in R&D reflected expanded clinical development, including ivosidenib, and greater internal and external program costs. No operating margin or product margin is meaningful given the absence of product sales and continuing development-stage losses. The balance sheet lists no borrowings; liabilities chiefly include deferred collaboration revenue, accrued expenses and lease-related amounts.
Operating cash flow was positive largely because of the $200 million Celgene upfront payment under the 2016 collaboration agreement, substantially deferred for accounting purposes, along with collaboration reimbursements and a $25 million milestone. Investing cash flow was $(119.4) million and financing cash flow was $169.8 million, including net proceeds from a September 2016 stock offering. Agios estimated its year-end liquidity, anticipated interest and collaboration reimbursements would fund operations and capital needs through at least the end of 2018, excluding additional program-specific milestones.
Fourth-quarter 2016 revenue was $22.6 million, operating loss was $57.4 million, net loss was $56.5 million and loss per share was $1.34. Fourth-quarter 2015 comparatives were revenue of $6.2 million, operating loss of $40.9 million, net loss of $40.6 million and loss per share of $1.08.
Business and material developments
- Enasidenib (IDH2): Celgene submitted an NDA in December 2016 for relapsed or refractory AML and funds the program’s development. Agios received a $25 million clinical milestone in January 2016 and may receive further milestones and royalties.
- Ivosidenib (IDH1): Agios regained worldwide development and commercial rights effective August 15, 2016, and expects to fund future costs. The company planned an NDA submission for relapsed or refractory AML by the end of 2017 and intended to start the AGILE Phase 3 combination trial in the first half of 2017. ClarIDHy, a Phase 3 cholangiocarcinoma trial, began in December 2016.
- AG-348 (pyruvate kinase deficiency): Phase 2 DRIVE-PK data showed hemoglobin increases greater than 1.0 g/dL in 15 of 32 evaluable patients; Agios announced plans to advance the drug into pivotal development. The filing notes that response may vary by genotype and that further data are needed.
- AG-881: The Phase 1 program continued under a worldwide Celgene collaboration with shared development costs and profits.
- AG-519: Agios discontinued development and withdrew its IND in December after FDA notification of a clinical hold related to a case of drug-induced cholestatic hepatitis.
- Celgene relationship: The new 2016 global research collaboration focused on metabolic immuno-oncology generated a $200 million upfront payment. Agios also has collaboration-dependent revenue and development arrangements; Celgene controls or shares rights across several programs, while Agios bears the future costs for ivosidenib and AG-348.
Outlook, risks and unusual items
Management expected expenses and operating losses to continue rising as clinical programs advanced, research expanded and the company prepared for possible commercialization. There was no product-sales guidance or assurance of profitability. The runway estimate depends on assumptions about spending, clinical progress and collaboration reimbursements; management cautioned that funds could be consumed faster than expected.
- Clinical efficacy, safety, trial enrollment, regulatory review and approval remain uncertain; early-stage results may not predict pivotal-trial outcomes.
- Agios depends heavily on Celgene for collaboration funding and on third parties for clinical research and manufacturing. It had no long-term manufacturing supply agreements or redundant bulk-drug supply arrangements.
- Precision-medicine programs may face patient-enrollment constraints, and companion diagnostics may require separate regulatory approval.
- Commercial prospects depend on market acceptance, reimbursement, pricing, competition, intellectual-property protection and successful manufacturing and commercialization.
- Cash and marketable securities are exposed to interest-rate and credit-market movements; the company also has unhedged foreign-currency exposure from certain contracts. Management did not consider a 10% immediate interest-rate change material to portfolio fair value.
- The $200 million Celgene upfront payment materially supported liquidity, but was not equivalent to recurring product revenue. Collaboration revenue also reflects milestone recognition and estimates of performance obligations; a $10.8 million change in estimate increased 2016 revenue.
- Agios reported effective disclosure controls and internal control over financial reporting; the auditor issued unqualified opinions on the financial statements and internal controls.
Investor facts to verify
- Whether the enasidenib NDA was accepted and its subsequent FDA review and outcome.
- Progress, spending, enrollment and results for ivosidenib’s planned NDA and AGILE trial, as well as ClarIDHy.
- Whether AG-348 entered pivotal development and whether later data substantiate the DRIVE-PK response and genotype observations.
- Cash use and runway relative to the stated end-of-2018 estimate, including the effect of Agios funding ivosidenib development.
- How much reported collaboration revenue represents cash received versus deferred revenue, reimbursements, milestones and accounting estimate changes.
- Any further safety or regulatory developments involving AG-519 or other pipeline candidates, and any changes to Celgene collaboration terms or program commitments.